Evgen Pharma Share Discussion Threads

[wanobi] 15/12/2020 13:26

a sniff of success and the MCAP here will be seen as ridiculous one thinks, fingers crossed, GLA Holders, Cheers Wan :-)

[bumpa33] 15/12/2020 13:20

Still here Rb, busy with other things at the mo though.

[yus777] 15/12/2020 13:19

remember folks this is new terrotrey short term 14.75p any decent news this will rocket

[daftweejock] 15/12/2020 13:17

Getting ready for a run?

[yus777] 15/12/2020 13:14

another 80k buy at 10p

[yus777] 15/12/2020 13:13

70k buy at 10.2p n a 25k at same price hold next leg up n load up very difficult to buy

[yus777] 15/12/2020 13:08

trying to shake weak holders out hmm

[dutch123] 15/12/2020 13:06

managed a few 10.1669.

[yus777] 15/12/2020 12:57

premium to buy 10.5p

[yus777] 15/12/2020 12:56

nt trade only

[yus777] 15/12/2020 12:55

all resistance broken boom

[moneymunch] 15/12/2020 12:51

News on SFX-01's evaluation for CKD and NASH at anytime. Gla ;-)


13/2/20

University of Rochester Collaboration

Evgen Pharma (Evgen) and The University of Rochester School of Medicine and Dentistry have entered into a Memorandum of Understanding to advance SFX-01 towards a clinical trial in chronic kidney disease (CKD).

Thu Le, Professor of Medicine, and Chief of the Division of Nephrology at the University of Rochester Medical Center said: "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD. Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing."

Dr Stephen Franklin, CEO of Evgen Pharma, commented:

"We are delighted to be supporting the work of such a respected team and prestigious university. We very much hope the proposed trial will generate data demonstrating that SFX-01 could potentially improve the lives of patients suffering from CKD."

.........


5/12/19

Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it has entered into a Memorandum of Understanding with the The University of Dundee ("The University") to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis ("NASH") and liver fibrosis. Evgen has agreed to supply SFX-01 to support a potential future clinical trial led by John Dillon, Professor of Hepatology and Gastrenterology in the University's School of Medicine.

With the assistance of Evgen, Professor Dillon will lead the process to secure appropriate grant funding and obtain clinical trial regulatory approval. The intention is to utilise advanced MRI scanning technology to investigate whether SFX-01 can reverse the hallmarks of NASH in a proof-of-concept clinical trial. Clinical data arising from a successful trial will support subsequent development, regulatory approval and commercialisation of SFX-01 in NASH and liver fibrosis. Evgen will be granted an option to the clinical data on fair commercial terms to enable it to advance development and commercialisation.

Non-alcoholic fatty liver disease ("NAFLD") is now regarded as the most common liver condition in the developed world, affecting up to 30% of the general population. NAFLD represents a spectrum of phenotypes ranging from simple steatosis (fatty infiltration), through NASH to cirrhosis. Approximately 30% of adults in the general population have NAFLD, and 10%-20% of these have NASH. Amongst patients with NASH, 20-30% are at risk of developing cirrhosis and subsequently dying from end-stage liver disease within 20 years. In view of the tens of thousands of individuals who are likely to develop NASH in the next decade, it is clear that this disease will represent a major burden to healthcare in the UK.

Professor John Dillon and colleagues have previously published research that showed that drug-induced activation of the Nrf2 pathway could reverse insulin resistance, suppress hepatic steatosis, and mitigated against NASH and liver fibrosis. On this basis, Professor John Dillon approached Evgen, the developer of SFX-01, a development stage drug that is known to activate the Nrf2 pathway and has demonstrated excellent safety and tolerability in previous clinical trials.

John Dillon, Professor of Hepatology and Gastrenterology at the University of Dundee's the School of Medicine said: "We are delighted that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology."

[hodhasharon] 15/12/2020 12:44

My analysis shows the next move terminating around 22p.

[peanut100] 15/12/2020 12:42

Love the fact still only capped at £13.4m - steal of the century

[moneymunch] 15/12/2020 12:39

HIGH POINT, N.C.,

Dec. 15, 2020 (GLOBE NEWSWIRE) --

vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compound, HPP971.

Anteris Bio, a newly-formed portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman, will focus on developing HPP971 as a new therapy for the treatment of renal disease.

HPP971 is vTv’s most advanced oral, small molecule activator of the Nrf2 pathway (nuclear factor erythroid 2-related factor 2) within its portfolio of promising Nrf2 compounds. HPP971 has completed two phase 1 studies to date. Under the terms of the agreement, Anteris will pay vTv an upfront payment of $2 million and vTv may be eligible for up to $151 million of future development, regulatory and commercial sales milestones, as well as royalties on annual net sales at a low double-digit rate in exchange for worldwide development and commercialization rights to the compound. In addition, vTv will receive a minority equity interest in Anteris Bio.

“The Nrf2 pathway is a promising, novel target for combating many diseases related to oxidative stress, including renal disease,” said Steve Holcombe, president and chief executive officer of vTv Therapeutics. “We’re thrilled to partner with Anteris to further the development of HPP971. With a focus in renal disease and a strategic partnership with TrialSpark, they will have the ability to efficiently develop HPP971 to ultimately bring a potential new treatment option to patients suffering from kidney disease.”

Chronic kidney disease (CKD) is one of the most significant global health challenges and a leading cause of mortality, both directly and as a key risk factor for cardiovascular disease. Globally, it is estimated that nearly 700 million individuals suffer from CKD, and CKD is directly responsible for over 1 million deaths annually. Clear unmet medical need exists in renal disease as therapies have traditionally revolved around treatment of symptoms (e.g. hypertension, renal failure). HPP971, to be renamed ANT-401, is a small molecule activator of Nrf2, a mechanism which has disease modifying potential across multiple etiologies of renal disease. Nrf2 is a transcription factor required for the expression of many antioxidant genes regulated by the ARE promoter sequence. ANT-401 activates Nrf2 through the inhibition of Bach1, a transcription repressor that prevents Nrf2 activity in the nucleus.

vTv will continue to explore further internal development and partnership opportunities for the remaining molecules in its portfolio of Nrf2 activators.

[yus777] 15/12/2020 12:29

nt trade only

[yus777] 15/12/2020 12:19

break 9.8p after clear path to 15p

[yus777] 15/12/2020 12:17

zak will be all over this one fill your boots up

[moneymunch] 15/12/2020 12:04

Cheap as chips....Grab 'em while you can....a sudden and significant re-rate at anytime with news possible on multiple fronts, and interim results from SFX-01's Covid-19 patient trials coming soon , following the recruitment and assessment of the first 100 patients administered......Positive results would very likely take the share price into orbit....Jim Mellon got in early before any substantial rise in value of Evgen, and highly possible that any other potential JV partner might be having the same idea. Gla ;-)

[riggerbeautz] 15/12/2020 12:00

Good to see you’re still around Bumpa, keeping the faith with these :)

[bumpa33] 15/12/2020 08:17

no prob wan, just noted the same yesterday too?

[wanobi] 15/12/2020 08:12

many thanx for the heads up on that Bumpa, cheers Wan :-)

[bumpa33] 15/12/2020 08:10

interesting, 500k total on the bid in the auction this morning...

[moneymunch] 14/12/2020 21:50

Another failed treatment, and presumably not great news for SAR who announced today their focus on investigation of Tyk2/ Jak1 inhibitors potential for Covid-19.

.........

Incyte’s ruxolitinib fails to meet primary endpoint in Covid-19 trial

14th December 2020 (Last Updated December 14th, 2020 14:08)

Incyte has announced that the Phase III RUXCOVID study of JAK1 / JAK2 inhibitor ruxolitinib (Jakafi) for treating patients aged 12 years and above with Covid-19-associated cytokine storm did not meet its primary endpoint.